Immutep Ltd
eftilagimod alfa (efti)
soft tissue sarcoma
Date
TBD
FDA decision · Date TBD estimated
What's at stake
An FDA complete response letter on eftilagimod alfa (efti) for soft tissue sarcoma is in focus around Date TBD.
Primary source
· SEC 6-K
verified 14h ago
“Translational data from EFTISARC-NEO shared in an oral presentation at CTOS 2025 demonstrate efti’s strong immune system activation with statistically-significant increases in multiple cytokines / chemokines and correlation between key immu”